Evotec (EVO) Projected to Release Earnings on Thursday

Evotec (NASDAQ:EVO) is anticipated to issue its Q2 2026 resultson Thursday, August 13th. Analysts expect the company to announce earnings of ($0.0461) per share and revenue of $174.01 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 13, 2026 at 6:00 AM ET.

Evotec Price Performance

Shares of EVO opened at $2.08 on Tuesday. The company has a current ratio of 1.68, a quick ratio of 1.60 and a debt-to-equity ratio of 0.43. The stock has a 50 day simple moving average of $2.44 and a 200 day simple moving average of $2.84. Evotec has a 52-week low of $1.89 and a 52-week high of $4.27.

Institutional Trading of Evotec

Hedge funds have recently modified their holdings of the stock. Millennium Management LLC acquired a new stake in Evotec during the fourth quarter worth approximately $317,000. LPL Financial LLC raised its stake in Evotec by 25.1% in the fourth quarter. LPL Financial LLC now owns 94,625 shares of the company’s stock valued at $291,000 after purchasing an additional 18,964 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in Evotec during the fourth quarter worth about $110,000. Citadel Advisors LLC lifted its position in Evotec by 186.1% during the third quarter. Citadel Advisors LLC now owns 96,045 shares of the company’s stock worth $349,000 after purchasing an additional 62,471 shares during the period. Finally, Snowden Capital Advisors LLC acquired a new stake in Evotec during the second quarter worth about $122,000. Institutional investors and hedge funds own 5.81% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Wall Street Zen cut Evotec from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Evotec in a report on Tuesday, July 21st. HC Wainwright cut their target price on Evotec from $7.00 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday, July 15th. TD Cowen cut shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 price target for the company. in a research note on Wednesday, July 15th. Finally, Berenberg Bank lowered shares of Evotec from a “buy” rating to a “hold” rating in a research report on Thursday, July 16th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $3.00.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.